Nothing Special   »   [go: up one dir, main page]

MX2021004120A - Regimen de dosificacion para antagonistas de tfpi. - Google Patents

Regimen de dosificacion para antagonistas de tfpi.

Info

Publication number
MX2021004120A
MX2021004120A MX2021004120A MX2021004120A MX2021004120A MX 2021004120 A MX2021004120 A MX 2021004120A MX 2021004120 A MX2021004120 A MX 2021004120A MX 2021004120 A MX2021004120 A MX 2021004120A MX 2021004120 A MX2021004120 A MX 2021004120A
Authority
MX
Mexico
Prior art keywords
dosage regimen
tfpi
antagonists
tfpi antagonists
antigen
Prior art date
Application number
MX2021004120A
Other languages
English (en)
Inventor
Steven Arkin
Tong Zhu
Matthew H Cardinal
Chay Ngee Lim
Satyaprakash Nayak
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2021004120A publication Critical patent/MX2021004120A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan regímenes de dosificación para el tratamiento de trastornos de la coagulación usando anticuerpos anti-TFPI. Los métodos comprenden administrar a un sujeto que lo necesita una dosis inicial de aproximadamente 50 mg a 500 mg de un anticuerpo anti-TFPI o de un fragmento de unión a antígeno del mismo.
MX2021004120A 2018-10-11 2019-10-09 Regimen de dosificacion para antagonistas de tfpi. MX2021004120A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862744481P 2018-10-11 2018-10-11
US201962802401P 2019-02-07 2019-02-07
PCT/IB2019/058597 WO2020075083A1 (en) 2018-10-11 2019-10-09 Dosage regimen for tfpi antagonists

Publications (1)

Publication Number Publication Date
MX2021004120A true MX2021004120A (es) 2021-09-10

Family

ID=68242804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004120A MX2021004120A (es) 2018-10-11 2019-10-09 Regimen de dosificacion para antagonistas de tfpi.

Country Status (11)

Country Link
US (1) US20210395391A1 (es)
EP (1) EP3863664A1 (es)
JP (2) JP7289913B2 (es)
KR (2) KR20210074335A (es)
CN (1) CN113645995A (es)
AU (1) AU2019359540B2 (es)
BR (1) BR112021006223A2 (es)
CA (1) CA3115607A1 (es)
IL (1) IL281968B2 (es)
MX (1) MX2021004120A (es)
WO (1) WO2020075083A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302353A (en) 2015-08-19 2023-06-01 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
CN117285632A (zh) * 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 针对tfpi的单克隆抗体及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE395413T1 (de) 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP2379599B1 (en) 2008-12-22 2015-09-02 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor (tfpi)
RU2562114C2 (ru) * 2008-12-22 2015-09-10 Ново Нордиск А/С Антитела против ингибитора метаболического пути тканевого фактора
AU2014200227A1 (en) * 2008-12-22 2014-01-30 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
MX2012010198A (es) * 2010-03-01 2012-10-03 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).
EP2588499B1 (en) 2010-06-30 2020-04-08 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
CN105452298B (zh) 2013-03-15 2021-08-31 拜尔健康护理有限责任公司 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
EP2970499B1 (en) 2013-03-15 2022-08-10 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
WO2015007880A1 (en) 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
IL302353A (en) * 2015-08-19 2023-06-01 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof

Also Published As

Publication number Publication date
JP2022512635A (ja) 2022-02-07
WO2020075083A1 (en) 2020-04-16
EP3863664A1 (en) 2021-08-18
KR20210074335A (ko) 2021-06-21
CN113645995A (zh) 2021-11-12
JP7289913B2 (ja) 2023-06-12
IL281968B2 (en) 2025-02-01
IL281968A (en) 2021-05-31
JP2023030081A (ja) 2023-03-07
AU2019359540A1 (en) 2021-04-29
CA3115607A1 (en) 2020-04-16
BR112021006223A2 (pt) 2021-07-06
IL281968B1 (en) 2024-10-01
US20210395391A1 (en) 2021-12-23
KR20240135884A (ko) 2024-09-12
AU2019359540B2 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
MX2020005166A (es) Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos.
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
AR104812A1 (es) Combinaciones terapéuticas y métodos para tratar neoplasias
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
MX2016004411A (es) Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1).
DK1684869T3 (da) Fremgangsmåde til terapi af B-celle-relaterede cancersygdomme
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
MX2020012755A (es) Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37).
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
CY1123350T1 (el) Θεραπευτικα σχηματα καi μεθοδοι αντιμετωπισης σκληρυνσης κατα πλακας μεσω χρησης οφατουμουμαμπης
MX2021004120A (es) Regimen de dosificacion para antagonistas de tfpi.
JP2017537927A5 (es)
CO2021014370A2 (es) Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen
BR112017004590A2 (pt) métodos para o tratamento de doença autoimune com o uso de um anticorpo de domínio direcionado contra cd40l
MX2022005628A (es) Regimen de dosificacion para agentes anti-bcma.
NZ773583A (en) Methods of treating psoriasis
MX2021004603A (es) Dosificacion.
WO2019087133A8 (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists
IL288636A (en) Dosage regimen and management for the treatment or prevention of c5-related diseases using the anti-c5 antibody crobalimab
HRP20211478T1 (hr) Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka
WO2020092533A3 (en) Methods of treatment using anti-cd123 immunoconjugates
MX2021012848A (es) Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn.